Secondary Logo

Journal Logo

Articles by Mark A. Boyd, BMBS

Bone Mineral Density Over 96 Weeks in Adults Failing First-Line Therapy Randomized to Raltegravir/Lopinavir/Ritonavir Compared With Standard Second-Line Therapy

Haskelberg, Hila; Mallon, Patrick W.G.; Hoy, Jennifer; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 67(2):161-168, October 1st, 2014.

A Randomized Study of Pharmacokinetics, Efficacy, and Safety of 2 Raltegravir Plus Atazanavir Strategies in ART-Treated Adults

Carey, Dianne; Pett, Sarah L.; Bloch, Mark; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 60(2):143-149, June 1st, 2012.

Pharmacokinetics of Indinavir/Ritonavir (800/100 mg) in Combination With Efavirenz (600 mg) in HIV-1-Infected Subjects

Boyd, Mark A.; Aarnoutse, Rob E.; Ruxrungtham, Kiat; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 34(2):134-139, October 1st, 2003.